{
    "nct_id": "NCT05822752",
    "official_title": "A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC",
    "inclusion_criteria": "* Child-Pugh A classification.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.\n* Received an immune checkpoint inhibitor in first-line (1L) hepatocellular carcinoma (HCC) treatment regimen.\n* Adequate hematologic and end-organ function.\n* Tissue biopsy at screening.\n* Disease that is not amenable to surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.\n* Prior treatment with an approved tyrosine kinase inhibitor (for example sorafenib or Lenvatinib) in 1L HCC treatment regimen.\n* History of malignancy other than hepatocellular carcinoma (HCC) within 5 years prior to screening.\n* Hepatic encephalopathy or requirement for medications to prevent or control encephalopathy.\n* Moderate or severe ascites requiring recurrent non-pharmacologic intervention to maintain symptomatic control.\n* Coinfection with active HBV infection and active HCV infection.\n* Prior history of grade 3 or higher immune-mediated adverse event or discontinuation due to immune-mediated adverse events.\n* Prior history of recurrent grade 2 or higher interstitial lung disease/pneumonitis.",
    "miscellaneous_criteria": ""
}